机译:治疗达比甙患者的两年后随访,用于在心房颤动中卒中预防:全球注册表关于心房颤动患者的长期抗血栓处理(Gloria-AF)登记处
Department of Thrombosis and Hemostasis Leiden University Medical Center;
RTI Health Solutions Research Triangle Institute Research Triangle Park;
Department of Health Research Methods Evidence and Impact McMaster University;
Medical Department Boehringer Ingelheim Pharma GmbH &
Co. KG;
Department of Neurology University of Duisburg-;
Clínica y Maternidad Suizo Argentina;
Icahn School of Medicine at Mount Sinai;
Cardiology Department Atrial Fibrillation Center Beijing AnZhen Hospital Capital Medical;
Global Epidemiology Department Boehringer Ingelheim Pharma GmbH &
Co. KG Ingelheim;
Biostatistics and Data Sciences Department Boehringer Ingelheim Pharma GmbH &
Co. KG Ingelheim;
Biostatistics and Data Sciences Department Boehringer Ingelheim Pharmaceuticals Inc;
Global Epidemiology Department Boehringer Ingelheim Pharma GmbH &
Co. KG Ingelheim;
Institute of Cardiovascular Sciences University of Birmingham UK and Aalborg Thrombosis Research;
机译:治疗达比甙患者的两年后随访,用于在心房颤动中卒中预防:全球注册表关于心房颤动患者的长期抗血栓处理(Gloria-AF)登记处
机译:新诊断的心房颤动患者的抗血栓治疗模式以及非洲/中东地区的Dabigatran治疗患者的2年后续结果:II阶段来自Gloria-AF注册表计划
机译:心房颤动患者长期口服抗血栓治疗的全球注册管理系统的设计和原理:房颤患者长期口服抗血栓治疗的全球注册管理系统
机译:用密码脑卒中患者经皮型卵形卵形卵形卵巢经皮和小间隔缺陷后心房颤动的发生率:案例对照研究
机译:在美国引入达比加群后预防心房颤动患者中风后华法林在抗凝临床中的成本效益
机译:非维生素K拮抗剂口服抗凝剂时代之前在房颤患者中使用抗血栓治疗:房颤患者长期口服抗血栓治疗全球注册表(GLORIA-AF)I队列
机译:心房颤动(GLORIA-AF)患者长期口服抗血栓治疗全球注册计划:北美DABIGATRAN和VKA人群基线特征的首次评估